Top-Rated StocksTop-RatedNASDAQ:LEGN Legend Biotech (LEGN) Stock Price, News & Analysis $34.08 +0.06 (+0.18%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends About Legend Biotech Stock (NASDAQ:LEGN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Legend Biotech alerts:Sign Up Key Stats Today's Range$33.76▼$34.8950-Day Range$33.01▼$49.6852-Week Range$32.50▼$70.13Volume1.64 million shsAverage Volume1.14 million shsMarket Capitalization$6.22 billionP/E RatioN/ADividend YieldN/APrice Target$81.54Consensus RatingBuy Company OverviewLegend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.Read More… Legend Biotech Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks31st Percentile Overall ScoreLEGN MarketRank™: Legend Biotech scored higher than 31% of companies evaluated by MarketBeat, and ranked 788th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingLegend Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 13 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageLegend Biotech has only been the subject of 4 research reports in the past 90 days.Read more about Legend Biotech's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Legend Biotech are expected to grow in the coming year, from ($1.23) to ($0.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Legend Biotech is -35.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Legend Biotech is -35.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLegend Biotech has a P/B Ratio of 4.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.04% of the outstanding shares of Legend Biotech have been sold short.Short Interest Ratio / Days to CoverLegend Biotech has a short interest ratio ("days to cover") of 17.5, which indicates bearish sentiment.Change versus previous monthShort interest in Legend Biotech has recently increased by 3.93%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLegend Biotech does not currently pay a dividend.Dividend GrowthLegend Biotech does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted13.04% of the outstanding shares of Legend Biotech have been sold short.Short Interest Ratio / Days to CoverLegend Biotech has a short interest ratio ("days to cover") of 17.5, which indicates bearish sentiment.Change versus previous monthShort interest in Legend Biotech has recently increased by 3.93%, indicating that investor sentiment is decreasing. News and Social Media2.0 / 5News Sentiment0.66 News SentimentLegend Biotech has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Legend Biotech this week, compared to 5 articles on an average week.Search InterestOnly 1 people have searched for LEGN on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Legend Biotech to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Legend Biotech insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.02% of the stock of Legend Biotech is held by insiders.Percentage Held by Institutions70.89% of the stock of Legend Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Legend Biotech's insider trading history. Receive LEGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Legend Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address LEGN Stock News HeadlinesBrokerages Set Legend Biotech Co. (NASDAQ:LEGN) PT at $81.54December 20 at 2:43 AM | americanbankingnews.comLegend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceDecember 19 at 8:01 AM | globenewswire.comURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.December 22, 2024 | Crypto Swap Profits (Ad)William Blair Sticks to Its Hold Rating for Legend Biotech (LEGN)December 11, 2024 | markets.businessinsider.comPositive Prospects for Legend Biotech’s CARVYKTI: Buy Rating Backed by Real-World Safety Data and Competitive PositionDecember 11, 2024 | markets.businessinsider.comDeep Dive Into Legend Biotech Stock: Analyst Perspectives (10 Ratings)December 10, 2024 | benzinga.comCARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple MyelomaDecember 9, 2024 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Disc Medicine (IRON) and BridgeBio Pharma (BBIO)December 9, 2024 | markets.businessinsider.comSee More Headlines LEGN Stock Analysis - Frequently Asked Questions How have LEGN shares performed this year? Legend Biotech's stock was trading at $60.17 at the start of the year. Since then, LEGN stock has decreased by 43.4% and is now trading at $34.08. View the best growth stocks for 2024 here. How were Legend Biotech's earnings last quarter? Legend Biotech Co. (NASDAQ:LEGN) issued its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.34) EPS for the quarter, beating analysts' consensus estimates of ($0.56) by $0.22. The firm's quarterly revenue was up 66.9% compared to the same quarter last year. When did Legend Biotech IPO? Legend Biotech (LEGN) raised $350 million in an initial public offering (IPO) on Friday, June 5th 2020. The company issued 18,400,000 shares at a price of $18.00-$20.00 per share. Morgan Stanley, J.P. Morgan Securities and Jefferies served as the underwriters for the IPO. Who are Legend Biotech's major shareholders? Top institutional investors of Legend Biotech include FMR LLC (10.05%), Westfield Capital Management Co. LP (2.76%), Massachusetts Financial Services Co. MA (1.25%) and Janus Henderson Group PLC (1.20%). How do I buy shares of Legend Biotech? Shares of LEGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Legend Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Legend Biotech investors own include NVIDIA (NVDA), Broadcom (AVGO), Adobe (ADBE), Meta Platforms (META), Arista Networks (ANET), Jabil (JBL) and e.l.f. Beauty (ELF). Company Calendar Last Earnings11/12/2024Today12/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LEGN CUSIPN/A CIK1801198 Webwww.legendbiotech.com Phone732-317-5050FaxN/AEmployees1,800Year FoundedN/APrice Target and Rating Average Stock Price Target$81.54 High Stock Price Target$94.00 Low Stock Price Target$60.00 Potential Upside/Downside+139.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($0.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-518,250,000.00 Net Margins-66.92% Pretax MarginN/A Return on Equity-29.69% Return on Assets-19.45% Debt Debt-to-Equity Ratio0.27 Current Ratio4.98 Quick Ratio4.90 Sales & Book Value Annual Sales$520.18 million Price / Sales11.97 Cash FlowN/A Price / Cash FlowN/A Book Value$6.88 per share Price / Book4.95Miscellaneous Outstanding Shares182,634,000Free Float182,597,000Market Cap$6.22 billion OptionableOptionable Beta0.08 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report This page (NASDAQ:LEGN) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersWall Street Icon: “You must get on the right side of this thing”I created one of the first quantitative analysis-based stock picking systems long before "quants" became a thi...InvestorPlace | SponsoredMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredThis is the worst sign for the U.S. stock market in 50 yearsThe Dow recently posted its worst losing streak since 1974. And one of America's most accurate analysts no...Stansberry Research | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Legend Biotech Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Legend Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.